Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription

Articles published in BMC Cancer

Retrieve available abstracts of 113 articles:
HTML format

Single Articles

    July 2021
  1. MARTINI C, DeNichilo M, King DP, Cockshell MP, et al
    CD36 promotes vasculogenic mimicry in melanoma by mediating adhesion to the extracellular matrix.
    BMC Cancer. 2021;21:765.
    PubMed     Abstract available

  2. COEN O, Corrie P, Marshall H, Plummer R, et al
    The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.
    BMC Cancer. 2021;21:761.
    PubMed     Abstract available

    June 2021
  3. CAI YJ, Ke LF, Zhang WW, Lu JP, et al
    Recurrent KRAS, KIT and SF3B1 mutations in melanoma of the female genital tract.
    BMC Cancer. 2021;21:677.
    PubMed     Abstract available

  4. DE FRANCA MNF, Isidorio RG, Bonifacio JHO, Dos Santos EWP, et al
    Anti-proliferative and pro-apoptotic activity of glycosidic derivatives of lawsone in melanoma cancer cell.
    BMC Cancer. 2021;21:662.
    PubMed     Abstract available

    May 2021
  5. SALMI S, Lin A, Hirschovits-Gerz B, Valkonen M, et al
    The role of FoxP3+ regulatory T cells and IDO+ immune and tumor cells in malignant melanoma - an immunohistochemical study.
    BMC Cancer. 2021;21:641.
    PubMed     Abstract available

  6. DALLE S, Mortier L, Corrie P, Lotem M, et al
    Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study.
    BMC Cancer. 2021;21:642.
    PubMed     Abstract available

  7. LI H, Yang L, Lai Y, Wang X, et al
    Genetic alteration of Chinese patients with rectal mucosal melanoma.
    BMC Cancer. 2021;21:623.
    PubMed     Abstract available

  8. TYCIAKOVA S, Valova V, Svitkova B, Matuskova M, et al
    Overexpression of TNFalpha induces senescence, autophagy and mitochondrial dysfunctions in melanoma cells.
    BMC Cancer. 2021;21:507.
    PubMed     Abstract available

    April 2021
  9. DING Y, Jiang R, Chen Y, Jing J, et al
    Comparing the characteristics and predicting the survival of patients with head and neck melanoma versus body melanoma: a population-based study.
    BMC Cancer. 2021;21:420.
    PubMed     Abstract available

  10. WANG L, Chen F, Liu R, Shi L, et al
    Gene expression and immune infiltration in melanoma patients with different mutation burden.
    BMC Cancer. 2021;21:379.
    PubMed     Abstract available

  11. COROIU A, Moran C, Davine JA, Brophy K, et al
    Patient-identified early clinical warning signs of nodular melanoma: a qualitative study.
    BMC Cancer. 2021;21:371.
    PubMed     Abstract available

    March 2021
  12. MULDER EEAP, de Joode K, Litiere S, Ten Tije AJ, et al
    Early discontinuation of PD-1 blockade upon achieving a complete or partial response in patients with advanced melanoma: the multicentre prospective Safe Stop trial.
    BMC Cancer. 2021;21:323.
    PubMed     Abstract available

  13. KINIWA Y, Nakamura K, Mikoshiba A, Ashida A, et al
    Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
    BMC Cancer. 2021;21:287.
    PubMed     Abstract available

    February 2021
  14. NELL RJ, Menger NV, Versluis M, Luyten GPM, et al
    Involvement of mutant and wild-type CYSLTR2 in the development and progression of uveal nevi and melanoma.
    BMC Cancer. 2021;21:164.
    PubMed     Abstract available

  15. ALSHAMMARI ES, Aljagthmi AA, Stacy AJ, Bottomley M, et al
    ERK3 is transcriptionally upregulated by Np63alpha and mediates the role of Np63alpha in suppressing cell migration in non-melanoma skin cancers.
    BMC Cancer. 2021;21:155.
    PubMed     Abstract available

  16. TRAN KB, Kolekar S, Jabed A, Jaynes P, et al
    Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
    BMC Cancer. 2021;21:136.
    PubMed     Abstract available

    January 2021
  17. VECCHIATO A, Mocellin S, Del Fiore P, Tosti G, et al
    The surgical treatment of non-metastatic melanoma in a Clinical National Melanoma Registry Study Group (CNMR): a retrospective cohort quality improvement study to reduce the morbidity rates.
    BMC Cancer. 2021;21:8.
    PubMed     Abstract available

  18. TOOR K, Middleton MR, Chan K, Amadi A, et al
    Comparative efficacy and safety of adjuvant nivolumab versus other treatments in adults with resected melanoma: a systematic literature review and network meta-analysis.
    BMC Cancer. 2021;21:3.
    PubMed     Abstract available

    December 2020
  19. NAESER Y, Helgadottir H, Brandberg Y, Hansson J, et al
    TRIM study protocol - a prospective randomized multicenter Trial to assess the Role of Imaging during follow-up after radical surgery of stage IIB-C and III cutaneous malignant Melanoma.
    BMC Cancer. 2020;20:1197.
    PubMed     Abstract available

    November 2020
  20. REIS LB, Bakos RM, Vianna FSL, Macedo GS, et al
    Skin pigmentation polymorphisms associated with increased risk of melanoma in a case-control sample from southern Brazil.
    BMC Cancer. 2020;20:1069.
    PubMed     Abstract available

    October 2020
  21. WU CE, Yang CK, Peng MT, Huang PW, et al
    The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies.
    BMC Cancer. 2020;20:1018.
    PubMed     Abstract available

    September 2020
  22. ZHU J, Deng J, Zhang L, Zhao J, et al
    Reconstruction of lncRNA-miRNA-mRNA network based on competitive endogenous RNA reveals functional lncRNAs in skin cutaneous melanoma.
    BMC Cancer. 2020;20:927.
    PubMed     Abstract available

  23. SU W, Guan Y, Huang B, Wang J, et al
    Bioinformatic analysis reveals hub genes and pathways that promote melanoma metastasis.
    BMC Cancer. 2020;20:863.
    PubMed     Abstract available

    August 2020
  24. WEIGERT V, Jost T, Hecht M, Knippertz I, et al
    PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts.
    BMC Cancer. 2020;20:775.
    PubMed     Abstract available

    July 2020
  25. LINDENBERG M, Retel V, Rohaan M, van den Berg J, et al
    Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness.
    BMC Cancer. 2020;20:712.
    PubMed     Abstract available

  26. TANG J, Wan Q, Lu J
    The prognostic values of m6A RNA methylation regulators in uveal melanoma.
    BMC Cancer. 2020;20:674.
    PubMed     Abstract available

    June 2020
  27. ZOLFAGHARI MA, Karimi A, Kalantari E, Korourian A, et al
    A comparative study of long interspersed element-1 protein immunoreactivity in cutaneous malignancies.
    BMC Cancer. 2020;20:567.
    PubMed     Abstract available

    May 2020
  28. WANG X, Xiong H, Liang D, Chen Z, et al
    The role of SRGN in the survival and immune infiltrates of skin cutaneous melanoma (SKCM) and SKCM-metastasis patients.
    BMC Cancer. 2020;20:378.
    PubMed     Abstract available

    April 2020
  29. ALI A, Dumbrava M, Riddell K, Stewart N, et al
    Correlation between initial tumour volume and treatment duration on Dabrafenib: observation study of subjects with BRAF mutant melanoma on the BRF112680 trial.
    BMC Cancer. 2020;20:342.
    PubMed     Abstract available

  30. DAI WF, Beca JM, Croxford R, Isaranawatchai W, et al
    Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada.
    BMC Cancer. 2020;20:304.
    PubMed     Abstract available

  31. BOEGEHOLZ J, Brueggen CS, Pauli C, Dimitriou F, et al
    Challenges in diagnosis and management of neutropenia upon exposure to immune-checkpoint inhibitors: meta-analysis of a rare immune-related adverse side effect.
    BMC Cancer. 2020;20:300.
    PubMed     Abstract available

  32. STEEGHS EMP, Kroeze LI, Tops BBJ, van Kempen LC, et al
    Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
    BMC Cancer. 2020;20:291.
    PubMed     Abstract available

    March 2020
  33. LIU F, Hu L, Pei Y, Zheng K, et al
    Long non-coding RNA AFAP1-AS1 accelerates the progression of melanoma by targeting miR-653-5p/RAI14 axis.
    BMC Cancer. 2020;20:258.
    PubMed     Abstract available

    February 2020
  34. HOPKINS AM, Rathod AD, Rowland A, Kichenadasse G, et al
    Risk factors for severe rash with use of vemurafenib alone or in combination with cobimetinib for advanced melanoma: pooled analysis of clinical trials.
    BMC Cancer. 2020;20:157.
    PubMed     Abstract available

  35. COROIU A, Moran C, Bergeron C, Drapeau M, et al
    Short and long-term barriers and facilitators of skin self-examination among individuals diagnosed with melanoma.
    BMC Cancer. 2020;20:123.
    PubMed     Abstract available

    November 2019
  36. BOURN J, Rathore K, Donnell R, White W, et al
    Detection of carcinogen-induced bladder cancer by fluorocoxib A.
    BMC Cancer. 2019;19:1152.
    PubMed     Abstract available

  37. ZHANG Z, Imani S, Shasaltaneh MD, Hosseinifard H, et al
    The role of vascular mimicry as a biomarker in malignant melanoma: a systematic review and meta-analysis.
    BMC Cancer. 2019;19:1134.
    PubMed     Abstract available

  38. CALAPRE L, Warburton L, Millward M, Gray ES, et al
    Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report.
    BMC Cancer. 2019;19:1109.
    PubMed     Abstract available

  39. SOARES DE SA BC, de Macedo MP, Torrezan GT, Braga JCT, et al
    BAP1 tumor predisposition syndrome case report: pathological and clinical aspects of BAP1-inactivated melanocytic tumors (BIMTs), including dermoscopy and confocal microscopy.
    BMC Cancer. 2019;19:1077.
    PubMed     Abstract available

    October 2019
  40. YOSHINO K, Nakayama T, Ito A, Sato E, et al
    Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
    BMC Cancer. 2019;19:1019.
    PubMed     Abstract available

  41. TANAKA K, Nakamura Y, Mizutani T, Shibata T, et al
    Confirmatory trial of non-amputative digit preservation surgery for subungual melanoma: Japan Clinical Oncology Group study (JCOG1602, J-NAIL study protocol).
    BMC Cancer. 2019;19:1002.
    PubMed     Abstract available

  42. STOPPEK AK, Kebir S, Junker A, Keyvani K, et al
    Simultaneous primary cancer occurrence of melanoma and pulmonary adenocarcinoma in leptomeningeal metastases: a case report.
    BMC Cancer. 2019;19:995.
    PubMed     Abstract available

  43. LI L, Zhang S, Li H, Chou H, et al
    FGFR3 promotes the growth and malignancy of melanoma by influencing EMT and the phosphorylation of ERK, AKT, and EGFR.
    BMC Cancer. 2019;19:963.
    PubMed     Abstract available

    August 2019
  44. DOMA V, Karpati S, Raso E, Barbai T, et al
    Correction to: Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.
    BMC Cancer. 2019;19:853.
    PubMed     Abstract available

  45. LAWRANCE S, Bui C, Mahindra V, Arcorace M, et al
    Assessing a modified-AJCC TNM staging system in the New South Wales Cancer Registry, Australia.
    BMC Cancer. 2019;19:850.
    PubMed     Abstract available

  46. LEE J, Lee SJ, Kim K, Kim ST, et al
    Comprehensive molecular and clinical characterization of Asian melanoma patients treated with anti-PD-1 antibody.
    BMC Cancer. 2019;19:805.
    PubMed     Abstract available

  47. DOMA V, Karpathy S, Raso E, Barbai T, et al
    Dynamic and unpredictable changes in mutant allele fractions of BRAF and NRAS during visceral progression of cutaneous malignant melanoma.
    BMC Cancer. 2019;19:786.
    PubMed     Abstract available

  48. CASULA M, Paliogiannis P, Ayala F, De Giorgi V, et al
    Germline and somatic mutations in patients with multiple primary melanomas: a next generation sequencing study.
    BMC Cancer. 2019;19:772.
    PubMed     Abstract available

    July 2019
  49. MATTAINI KR, Sullivan MR, Lau AN, Fiske BP, et al
    Increased PHGDH expression promotes aberrant melanin accumulation.
    BMC Cancer. 2019;19:723.
    PubMed     Abstract available

  50. LOKHANDWALA PM, Tseng LH, Rodriguez E, Zheng G, et al
    Clinical mutational profiling and categorization of BRAF mutations in melanomas using next generation sequencing.
    BMC Cancer. 2019;19:665.
    PubMed     Abstract available

    June 2019
  51. XU M, Wang X, Pan Y, Zhao X, et al
    Blocking podoplanin suppresses growth and pulmonary metastasis of human malignant melanoma.
    BMC Cancer. 2019;19:599.
    PubMed     Abstract available

    May 2019
  52. VAN BUSSEL MTJ, Beijnen JH, Brandsma D
    Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review.
    BMC Cancer. 2019;19:519.
    PubMed     Abstract available

  53. MURALI VS, Chang BJ, Fiolka R, Danuser G, et al
    An image-based assay to quantify changes in proliferation and viability upon drug treatment in 3D microenvironments.
    BMC Cancer. 2019;19:502.
    PubMed     Abstract available

  54. JONES NM, Yang H, Zhang Q, Morales-Tirado VM, et al
    Natural killer cells and pigment epithelial-derived factor control the infiltrative and nodular growth of hepatic metastases in an Orthotopic murine model of ocular melanoma.
    BMC Cancer. 2019;19:484.
    PubMed     Abstract available

  55. JESPERSEN H, Bagge RO, Ullenhag G, Carneiro A, et al
    Concomitant use of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study): protocol for a multicenter phase II open label study.
    BMC Cancer. 2019;19:415.
    PubMed     Abstract available

    April 2019
  56. KLICKS J, Masslo C, Kluth A, Rudolf R, et al
    A novel spheroid-based co-culture model mimics loss of keratinocyte differentiation, melanoma cell invasion, and drug-induced selection of ABCB5-expressing cells.
    BMC Cancer. 2019;19:402.
    PubMed     Abstract available

    March 2019
  57. BLAIR CM, Walsh NM, Littman BH, Marcoux FW, et al
    Targeting B-Raf inhibitor resistant melanoma with novel cell penetrating peptide disrupters of PDE8A - C-Raf.
    BMC Cancer. 2019;19:266.
    PubMed     Abstract available

  58. KRUCKEL A, Moreira A, Frohlich W, Schuler G, et al
    Eosinophil-cationic protein - a novel liquid prognostic biomarker in melanoma.
    BMC Cancer. 2019;19:207.
    PubMed     Abstract available

    January 2019
  59. AN Q, Liu Z
    Comparative efficacy and safety of combination therapies for advanced melanoma: a network meta-analysis.
    BMC Cancer. 2019;19:43.
    PubMed     Abstract available

  60. AHN MY, Kim BJ, Kim HJ, Jin JM, et al
    Anti-cancer effect of dung beetle glycosaminoglycans on melanoma.
    BMC Cancer. 2019;19:9.
    PubMed     Abstract available

    December 2018
  61. MCQUADE JL, Homsi J, Torres-Cabala CA, Bassett R, et al
    A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma.
    BMC Cancer. 2018;18:1274.
    PubMed     Abstract available

  62. ROSE AM, Luo R, Radia UK, Kalirai H, et al
    Detection of mutations in SF3B1, EIF1AX and GNAQ in primary orbital melanoma by candidate gene analysis.
    BMC Cancer. 2018;18:1262.
    PubMed     Abstract available

  63. TERAS M, Viisileht E, Pahtma-Hall M, Rump A, et al
    Porcine circovirus type 2 ORF3 protein induces apoptosis in melanoma cells.
    BMC Cancer. 2018;18:1237.
    PubMed     Abstract available

  64. SEGAOULA Z, Primot A, Lepretre F, Hedan B, et al
    Isolation and characterization of two canine melanoma cell lines: new models for comparative oncology.
    BMC Cancer. 2018;18:1219.
    PubMed     Abstract available

    November 2018
  65. EWENS KG, Lalonde E, Richards-Yutz J, Shields CL, et al
    Comparison of Germline versus Somatic BAP1 Mutations for Risk of Metastasis in Uveal Melanoma.
    BMC Cancer. 2018;18:1172.
    PubMed     Abstract available

    October 2018
  66. IIDA Y, Salomon MP, Hata K, Tran K, et al
    Predominance of triple wild-type and IGF2R mutations in mucosal melanomas.
    BMC Cancer. 2018;18:1054.
    PubMed     Abstract available

  67. KHONG B, Lawson BO, Ma J, McGovern C, et al
    Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2.
    BMC Cancer. 2018;18:1007.
    PubMed     Abstract available

  68. SONG X, Guo C, Zheng Y, Wang Y, et al
    Post-transcriptional regulation of cancer/testis antigen MAGEC2 expression by TRIM28 in tumor cells.
    BMC Cancer. 2018;18:971.
    PubMed     Abstract available

    September 2018
  69. VILLAREAL MO, Sato Y, Matsuyama K, Isoda H, et al
    Correction to: Daphnane diterpenes inhibit the metastatic potential of B16F10 murine melanoma cells in vitro and in vivo.
    BMC Cancer. 2018;18:902.
    PubMed     Abstract available

  70. RETEL VP, Steuten LMG, Geukes Foppen MH, Mewes JC, et al
    Early cost-effectiveness of tumor infiltrating lymphocytes (TIL) for second line treatment in advanced melanoma: a model-based economic evaluation.
    BMC Cancer. 2018;18:895.
    PubMed     Abstract available

    August 2018
  71. SARAF RS, Datta A, Sima C, Hua J, et al
    An in-silico study examining the induction of apoptosis by Cryptotanshinone in metastatic melanoma cell lines.
    BMC Cancer. 2018;18:855.
    PubMed     Abstract available

  72. VILLAREAL MO, Sato Y, Matsuyama K, Isoda H, et al
    Daphnane diterpenes inhibit the metastatic potential of B16F10 murine melanoma cells in vitro and in vivo.
    BMC Cancer. 2018;18:856.
    PubMed     Abstract available

    Examining transcriptional changes to DNA replication and repair factors over uveal melanoma subtypes.
    BMC Cancer. 2018;18:818.
    PubMed     Abstract available

    July 2018
  74. MCEVOY AC, Warburton L, Al-Ogaili Z, Celliers L, et al
    Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.
    BMC Cancer. 2018;18:726.
    PubMed     Abstract available

  75. AMINI-ADLE M, Khanafer N, Le-Bouar M, Duru G, et al
    Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma.
    BMC Cancer. 2018;18:705.
    PubMed     Abstract available

    June 2018
  76. XIAO J, Egger ME, McMasters KM, Hao H, et al
    Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
    BMC Cancer. 2018;18:675.
    PubMed     Abstract available

  77. KHAN MA, Akram T, Sharif M, Shahzad A, et al
    An implementation of normal distribution based segmentation and entropy controlled features selection for skin lesion detection and classification.
    BMC Cancer. 2018;18:638.
    PubMed     Abstract available

  78. INOUE K, Tsubamoto H, Isono-Nakata R, Sakata K, et al
    Itraconazole treatment of primary malignant melanoma of the vagina evaluated using positron emission tomography and tissue cDNA microarray: a case report.
    BMC Cancer. 2018;18:630.
    PubMed     Abstract available

    May 2018
  79. GUIDA M, Tommasi S, Strippoli S, Natalicchio MI, et al
    The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale).
    BMC Cancer. 2018;18:552.
    PubMed     Abstract available

  80. MCDONALD MA, Sanghvi P, Bykowski J, Daniels GA, et al
    Unmasking of intracranial metastatic melanoma during ipilimumab/nivolumab therapy: case report and literature review.
    BMC Cancer. 2018;18:549.
    PubMed     Abstract available

  81. SI L, Zhang X, Xu Z, Jiang Q, et al
    Vemurafenib in Chinese patients with BRAF(V600) mutation-positive unresectable or metastatic melanoma: an open-label, multicenter phase I study.
    BMC Cancer. 2018;18:520.
    PubMed     Abstract available

    April 2018
  82. VOSOUGHI E, Lee JM, Miller JR, Nosrati M, et al
    Survival and clinical outcomes of patients with melanoma brain metastasis in the era of checkpoint inhibitors and targeted therapies.
    BMC Cancer. 2018;18:490.
    PubMed     Abstract available

  83. LI Y, Zhang J, Liu Y, Zhang B, et al
    MiR-30a-5p confers cisplatin resistance by regulating IGF1R expression in melanoma cells.
    BMC Cancer. 2018;18:404.
    PubMed     Abstract available

    February 2018
  84. SOOTICHOTE R, Thuwajit P, Singsuksawat E, Warnnissorn M, et al
    Compound A attenuates toll-like receptor 4-mediated paclitaxel resistance in breast cancer and melanoma through suppression of IL-8.
    BMC Cancer. 2018;18:231.
    PubMed     Abstract available

  85. BURAZOR I, Aviel-Ronen S, Imazio M, Goitein O, et al
    Metastatic cardiac tumors: from clinical presentation through diagnosis to treatment.
    BMC Cancer. 2018;18:202.
    PubMed     Abstract available

  86. MA Q, Shilkrut M, Zhao Z, Li M, et al
    Autoimmune comorbidities in patients with metastatic melanoma: a retrospective analysis of us claims data.
    BMC Cancer. 2018;18:145.
    PubMed     Abstract available

  87. ZAGER JS, Gastman BR, Leachman S, Gonzalez RC, et al
    Performance of a prognostic 31-gene expression profile in an independent cohort of 523 cutaneous melanoma patients.
    BMC Cancer. 2018;18:130.
    PubMed     Abstract available

    January 2018
  88. BUDDEN T, van der Westhuizen A, Bowden NA
    Sequential decitabine and carboplatin treatment increases the DNA repair protein XPC, increases apoptosis and decreases proliferation in melanoma.
    BMC Cancer. 2018;18:100.
    PubMed     Abstract available

  89. DEPCZYNSKI J, Dobbins T, Armstrong B, Lower T, et al
    Comparison of cancer incidence in Australian farm residents 45 years and over, compared to rural non-farm and urban residents - a data linkage study.
    BMC Cancer. 2018;18:33.
    PubMed     Abstract available

  90. KIKULSKA A, Rausch T, Krzywinska E, Pawlak M, et al
    Coordinated expression and genetic polymorphisms in Grainyhead-like genes in human non-melanoma skin cancers.
    BMC Cancer. 2018;18:23.
    PubMed     Abstract available

    December 2017
  91. SONG L, McNeil EM, Ritchie AM, Astell KR, et al
    Melanoma cells replicate through chemotherapy by reducing levels of key homologous recombination protein RAD51 and increasing expression of translesion synthesis DNA polymerase zeta.
    BMC Cancer. 2017;17:864.
    PubMed     Abstract available

  92. KUZBICKI L, Lange D, Stanek-Widera A, Chwirot BW, et al
    Prognostic significance of RBP2-H1 variant of JARID1B in melanoma.
    BMC Cancer. 2017;17:854.
    PubMed     Abstract available

    November 2017
  93. OZAKI Y, Shindoh J, Miura Y, Nakajima H, et al
    Serial pseudoprogression of metastatic malignant melanoma in a patient treated with nivolumab: a case report.
    BMC Cancer. 2017;17:778.
    PubMed     Abstract available

  94. CIRILO PDR, de Sousa Andrade LN, Correa BRS, Qiao M, et al
    MicroRNA-195 acts as an anti-proliferative miRNA in human melanoma cells by targeting Prohibitin 1.
    BMC Cancer. 2017;17:750.
    PubMed     Abstract available

  95. CHAGANI S, Wang R, Carpenter EL, Lohr CV, et al
    Ablation of epidermal RXRalpha in cooperation with activated CDK4 and oncogenic NRAS generates spontaneous and acute neonatal UVB induced malignant metastatic melanomas.
    BMC Cancer. 2017;17:736.
    PubMed     Abstract available

    October 2017
  96. MIDDLETON MR, Atkins MB, Amos K, Wang PF, et al
    Societal preferences for adjuvant melanoma health states: UK and Australia.
    BMC Cancer. 2017;17:689.
    PubMed     Abstract available

    September 2017
  97. VAN DER HIEL B, Haanen JBAG, Stokkel MPM, Peeper DS, et al
    Vemurafenib plus cobimetinib in unresectable stage IIIc or stage IV melanoma: response monitoring and resistance prediction with positron emission tomography and tumor characteristics (REPOSIT): study protocol of a phase II, open-label, multicenter st
    BMC Cancer. 2017;17:649.
    PubMed     Abstract available

    August 2017
  98. FALKENIUS J, Johansson H, Tuominen R, Frostvik Stolt M, et al
    Presence of immune cells, low tumor proliferation and wild type BRAF mutation status is associated with a favourable clinical outcome in stage III cutaneous melanoma.
    BMC Cancer. 2017;17:584.
    PubMed     Abstract available

  99. DE SMEDT J, Van Kelst S, Boecxstaens V, Stas M, et al
    Vitamin D supplementation in cutaneous malignant melanoma outcome (ViDMe): a randomized controlled trial.
    BMC Cancer. 2017;17:562.
    PubMed     Abstract available

  100. HARRER DC, Simon B, Fujii SI, Shimizu K, et al
    RNA-transfection of gamma/delta T cells with a chimeric antigen receptor or an alpha/beta T-cell receptor: a safer alternative to genetically engineered alpha/beta T cells for the immunotherapy of melanoma.
    BMC Cancer. 2017;17:551.
    PubMed     Abstract available

  101. HEPPT MV, Siepmann T, Engel J, Schubert-Fritschle G, et al
    Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.
    BMC Cancer. 2017;17:536.
    PubMed     Abstract available

    June 2017
  102. GAUSTAD JV, Simonsen TG, Andersen LMK, Rofstad EK, et al
    Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts.
    BMC Cancer. 2017;17:411.
    PubMed     Abstract available

    May 2017
  103. LI X, Li Z, Li X, Liu B, et al
    Mechanisms of Tanshinone II a inhibits malignant melanoma development through blocking autophagy signal transduction in A375 cell.
    BMC Cancer. 2017;17:357.
    PubMed     Abstract available

  104. GAMBICHLER T, Strutzmann S, Tannapfel A, Susok L, et al
    Paraneoplastic acral vascular syndrome in a patient with metastatic melanoma under immune checkpoint blockade.
    BMC Cancer. 2017;17:327.
    PubMed     Abstract available

    March 2017
  105. BHANGOO MS, Zhou JY, Ali SM, Madison R, et al
    Objective response to mTOR inhibition in a metastatic collision tumor of the liver composed of melanoma and adenocarcinoma with TSC1 loss: a case report.
    BMC Cancer. 2017;17:197.
    PubMed     Abstract available

    February 2017
  106. REIMAN A, Kikuchi H, Scocchia D, Smith P, et al
    Validation of an NGS mutation detection panel for melanoma.
    BMC Cancer. 2017;17:150.
    PubMed     Abstract available

    January 2017
  107. MERZOUG-LARABI M, Spasojevic C, Eymard M, Hugonin C, et al
    Protein kinase C inhibitor Go6976 but not Go6983 induces the reversion of E- to N-cadherin switch and metastatic phenotype in melanoma: identification of the role of protein kinase D1.
    BMC Cancer. 2017;17:12.
    PubMed     Abstract available

  108. O'SHEA SJ, Rogers Z, Warburton F, Ramirez AJ, et al
    Which symptoms are linked to a delayed presentation among melanoma patients? A retrospective study.
    BMC Cancer. 2017;17:5.
    PubMed     Abstract available

    December 2016
  109. CAISOVA V, Vieru A, Kumzakova Z, Glaserova S, et al
    Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.
    BMC Cancer. 2016;16:940.
    PubMed     Abstract available

  110. SCHOFFER O, Schulein S, Arand G, Arnholdt H, et al
    Tumour stage distribution and survival of malignant melanoma in Germany 2002-2011.
    BMC Cancer. 2016;16:936.
    PubMed     Abstract available

    November 2016
  111. SCHIROSI L, Strippoli S, Gaudio F, Graziano G, et al
    Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?
    BMC Cancer. 2016;16:905.
    PubMed     Abstract available

  112. CHIEN CH, Lee MJ, Liou HC, Liou HH, et al
    Growth hormone is increased in the lungs and enhances experimental lung metastasis of melanoma in DJ-1 KO mice.
    BMC Cancer. 2016;16:871.
    PubMed     Abstract available

    January 2016
  113. GRASSO C, Anaka M, Hofmann O, Sompallae R, et al
    Iterative sorting reveals CD133+ and CD133- melanoma cells as phenotypically distinct populations.
    BMC Cancer. 2016;16:726.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.